Research Article | Volume: 3, Issue: 4, April, 2013
Research Article | Volume: 3, Issue: 4, April, 2013
The present research work deals with the in- vitro dissolution study of developed sol to gel ocular drug delivery system of brimonidine for conjunctivitis during accelerated stability study. The formulation of brimonidine was developed and optimized formulation coded as X4Y2D containing optimized amount of sodium alginate and HPMC K100LvP was evaluated for the physico-chemical characterization and drug release initially and during accelerated stability study. The drug release was determined using fabricated continuous flow through cell apparatus. The difference between initial drug release and after three month drug release was 2.606% and the calculation was done for shelf life and found 2 years.
Manu babbar, Kanchan Kohli, Anil Bhandari, In-Vitro Dissolution Study and Shelf Life Calculation of Developed Sol-To-Gel Ocular Drug Delivery System of Brimonidine for Conjunctivitis During Accelerated Stability Study. J App Pharm Sci, 2013; 3 (04): 139- 142.
Year
Month
Clinical effectiveness and safety of brimonidine (0.2%) versus Dorzolamide (2.0%) in primary open angle
Sharma Neetu, Gupta Anita, Singh GursatinderCost effectiveness analysis of five different treatment alternatives in seasonal allergic conjunctivitis
Guvenc Kockaya, Albert WertheimerControlled drug release studies of valsartan using differently sulfonated methacryloxyacetophenone and methyl methacrylate co-polymer resins as drug carriers
High-Throughput Screening: The Hits and Leads of Drug Discovery- An Overview